MAP2K7 and melanoma: BRAF and mitogen-activated protein kinase kinase (MEK)-targeted therapies and immune checkpoint inhibitor (ICI) immunotherapy have led to remarkable improvements in response and survival outcomes in the advanced (unresectable stage III or IV melanoma) setting4,5.